loading page

Process evaluation of a pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among people with type 2 diabetes
  • +3
  • Gert Baas,
  • Stijn Crutzen,
  • Sanne Smits,
  • Petra Denig,
  • Katja Taxis,
  • Mette Heringa
Gert Baas
SIR Institute for Pharmacy Practice and Policy

Corresponding Author:[email protected]

Author Profile
Stijn Crutzen
University Medical Centre Groningen
Author Profile
Sanne Smits
University of Groningen
Author Profile
Petra Denig
University Medical Centre Groningen
Author Profile
Katja Taxis
University of Groningen
Author Profile
Mette Heringa
SIR Institute for Pharmacy Practice and Policy
Author Profile

Abstract

Background: A quasi-experimental study investigated a pharmacist-led intervention aimed at deprescribing among patients with type 2 diabetes at risk of hypoglycaemia. Objective: To evaluate the process of implementing the intervention in primary care in order to understand variations in implementation and outcomes. Methods: Mixed-methods study based on the Grant-framework, with 10 domains, including recruitment of patients, delivery of the intervention, and response of pharmacists and patients. Data collected were: administrative logs, semi-structured observations of patient consultations (n=8), interviews with pharmacists (n=16), and patient-reported experience measure (PREM) questionnaires (n=66; response 73%). Results: Ninety patients from 14 pharmacies were included. Although the selection of patients based on high hypoglycaemia-risk was considered useful, pharmacists experienced barriers to proposing deprescribing in patients with recent medication changes, patients without current health problems or hypoglycaemic events, and patients treated in secondary care. The consultation aid and deprescribing tool provided were evaluated positively by the pharmacists. The majority of patients were satisfied with the service and information that the pharmacists provided. Conclusion: Pharmacists and patients were positive about the intervention. Both groups valued the consultation on deprescribing, supported by tools. To optimise the effect, improvements can be made to patient selection and local agreements on proactive deprescribing.
31 Jan 2023Submitted to Basic & Clinical Pharmacology & Toxicology
06 Feb 2023Review(s) Completed, Editorial Evaluation Pending
06 Feb 2023Submission Checks Completed
06 Feb 2023Assigned to Editor
06 Feb 2023Reviewer(s) Assigned
27 Feb 2023Editorial Decision: Revise Major
26 May 20231st Revision Received
30 May 2023Submission Checks Completed
30 May 2023Assigned to Editor
30 May 2023Review(s) Completed, Editorial Evaluation Pending
30 May 2023Reviewer(s) Assigned
13 Jun 2023Editorial Decision: Revise Minor
13 Jul 20232nd Revision Received
14 Jul 2023Submission Checks Completed
14 Jul 2023Assigned to Editor
14 Jul 2023Review(s) Completed, Editorial Evaluation Pending
01 Aug 2023Editorial Decision: Accept